Neonatal myasthenia gravis (Q88652): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||
| Property / Knowledge Architect | |||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||
Normal rank | |||
Revision as of 14:59, 15 August 2026
Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_1274860004 |
||
| English | Neonatal myasthenia gravis |
Neonatal Myasthenia Gravis (MG) refers to the clinical MG syndrome caused by passively transferred maternal auto-antibodies to the newborn. This disease mechanism has been described for all three major forms of MG, including Acetylcholine receptor, Muscle-specific kinase and Lambert-Eaton myasthenic syndrome antibodies. Frequency is 10-30%. The neonates present with weakness, hypotonia, respiratory depression. The symptoms subside over 1 to 4 weeks. |
Statements
CID11:ID_1274860004
0 references
dki-india-ID_1274860004
0 references
Concluído
0 references
